Twice As Nice: Seattle Genetics, Merck & Co. Partner On Two Cancer Drugs
Companies Will Jointly Develop A Novel ADC And Commercialize Tukysa
Executive Summary
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.
You may also be interested in...
Seagen’s Tukysa Trial With Kadcyla Supports ADC Combination, But Safety Paramount
Results of the HER2CLIMB-02 study supported Tukysa combinations with antibody-drug conjugates. However, treatment discontinuations drew caution.
Merck & Co Could Be Plotting $30bn Bid For Seagen
A buyout of Seagen would boost Merck & Co’s goal of becoming the dominant player in oncology by 2025, but the deal is said to be far from done.
BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.